Saturday 17 October 2026
Export SXTC’s income statement to Excel — free account
China SXT Pharmaceuticals, Inc.
SXTC Healthcare Drug Manufacturers Specialty & Generic
China SXT Pharmaceuticals, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 million, down 34.6% from fiscal 2025.
0.07
0.00
0.00%
Follow SXTC
| Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | Mar '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | — | — | — | 4 | 5 | 4 | 4 | 8 | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 101.08 | 143.50 | 143.50 |
Altman Z-Score |
(0.84) | (1.00) | — | — | 3,060.50 | 12,820.94 | 202,635.77 | 15,873,085.12 | — | — |
P/S ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
7.29 | 2.19 | (1.11) | (1.51) | (0.51) | 0.42 | 1.53 | 6.57 | 4.36 | 4.34 |
Beneish M-Score |
(2.12) | (2.47) | (2.68) | (3.42) | (3.48) | 1.90 | (5.10) | (1.99) | 1.39 | (1.84) |
P/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
(5.94) | (3.79) | (2.11) | (3.04) | (1.83) | (1.34) | (0.05) | 0.00 | 0.00 | 0.00 |
EV/EBITDA |
2.66 | 1.69 | 0.95 | 1.36 | 2.01 | 4.65 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
2.87 | 2.79 | 3.08 | 20.65 | 7.98 | 5.16 | 0.85 | (3.72) | 0.00 | 0.00 |
EV/FCF |
2.90 | 2.80 | 2.93 | 16.41 | 6.79 | 3.73 | 0.18 | (3.72) | 0.00 | 0.00 |
Quick Ratio |
7.17 | 3.30 | 1.50 | 1.29 | 1.10 | 0.96 | 0.97 | 2.13 | 0.78 | 1.07 |
Current Ratio |
7.93 | 3.54 | 1.60 | 1.35 | 1.31 | 1.25 | 1.60 | 2.47 | 1.40 | 1.37 |
Net Debt/EBITDA |
3.86 | 6.67 | 4.18 | 2.60 | 2.78 | 7.19 | 0.56 | (4.73) | (0.15) | 0.14 |
Debt/Assets |
2.88% | 3.73% | 10.43% | 11.68% | 6.10% | 0.13% | 30.98% | 0.40% | 5.03% | 5.56% |
Debt/Equity |
0.03 | 0.05 | 0.17 | 0.23 | 0.12 | 0.00 | 0.72 | 0.01 | 0.12 | 0.16 |
Asset Turnover |
0.04 | 0.08 | 0.07 | 0.06 | 0.08 | 0.17 | 0.26 | 0.56 | 1.07 | 0.83 |
Operating CF/Net income |
0.65 | 0.71 | 0.62 | 0.01 | (0.05) | 0.48 | (0.09) | 0.16 | 1.62 | 0.25 |
Capex/Depreciation |
0.00 | 0.77 | (0.03) | (0.28) | (0.20) | (0.27) | (1.23) | (3.37) | (8.12) | (1.88) |
Interest Coverage |
(113.06) | (4.14) | (4.62) | (11.76) | (141.41) | (1.36) | (0.40) | 340.29 | 2,040.38 | 39.66 |
| (27.49%) | (22.50%) | (21.65%) | (38.15%) | (35.42%) | (21.67%) | (100.32%) | 21.39% | 46.22% | 91.32% | |
| (22.00%) | (14.75%) | (11.76%) | (18.81%) | (16.85%) | (9.77%) | (52.53%) | 12.25% | 18.15% | 20.21% | |
ROIC |
(175.91%) | 0.00% | (36.86%) | (453.09%) | (111.79%) | (51.90%) | (9.48%) | 58.66% | 33.86% | 47.93% |
Return on Tangible Assets |
(20.49%) | (21.37%) | (54.74%) | (99.13%) | (87.47%) | (45.15%) | (114.99%) | 14.76% | 45.81% | 65.42% |
Average Days of Receivables |
963.70 | 360.39 | 248.85 | 248.91 | 467.52 | 344.33 | 324.38 | 217.62 | 142.29 | 281.88 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
647.71% | 175.08% | 159.15% | 306.02% | 247.52% | 105.42% | 78.35% | 40.53% | 25.21% | 14.54% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
Share Based Compensation of Revenue |
466.19% | 0.00% | 18.26% | 28.13% | 89.71% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(82.82%) | (0.37%) | (0.56%) | (0.13%) | (0.14%) | 0.00% | 0.00% | 0.99% | 0.70% | 0.70% |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Revenue per Share |
133.89 | 17,409.00 | 0.00 | 0.00 | 2.50 | 6.64 | 0.84 | 0.34 | 0.35 | 0.24 |
Operating CF per Share |
(472.65) | (23,453.00) | 0.00 | 0.00 | 0.26 | (1.83) | 0.15 | 0.01 | 0.10 | 0.01 |
Capex per Share |
0.00 | 635.00 | 0.00 | 0.00 | (0.06) | (0.13) | (0.07) | (0.03) | (0.05) | (0.01) |
Free Cash Flow per Share |
(472.65) | (22,818.00) | 0.00 | 0.00 | 0.20 | (1.96) | 0.09 | (0.02) | 0.04 | 0.01 |
Cash per Share |
3,314.85 | 181,294.00 | 0.00 | 0.00 | 14.97 | 18.57 | 1.18 | 0.45 | 0.03 | 0.00 |
Shareholders Equity per Share |
3,494.99 | 154,398.00 | 0.00 | 0.00 | 15.79 | 22.18 | 1.52 | 0.54 | 0.16 | 0.09 |
Interest Debt per Share |
0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3,494.99 | 154,398.00 | 0.00 | 0.00 | 15.79 | 22.18 | 1.52 | 0.54 | 0.16 | 0.09 |
Free Cash Flow |
(4.02) | (2.28) | (1.94) | (0.15) | 0.21 | (1.41) | 0.53 | (0.37) | 0.87 | 0.11 |
Working Capital |
30.16 | 15.28 | 5.33 | 5.02 | 5.33 | 4.65 | 7.37 | 9.27 | 1.73 | 1.33 |
Capital Expenditures |
— | 0.06 | (0.01) | (0.07) | (0.06) | (0.09) | (0.41) | (0.61) | (1.05) | (0.19) |
Net Current Asset Value |
29.46 | 15.07 | 5.04 | 4.66 | 5.33 | 4.65 | 7.34 | 9.23 | 1.73 | 1.33 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | (0.04) | 0.00 | 0.04 | 0.02 | 0.02 | 0.08 | 0.09 | 0.15 | 0.04 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.63 | 0.46 | 0.62 | 0.26 | 0.26 | 0.24 | 0.21 | 0.16 | 0.15 | 0.20 |
Cash ROIC |
(6.82%) | (6.64%) | (6.81%) | (0.43%) | 0.60% | (4.80%) | 2.25% | (1.81%) | 20.09% | 4.81% |
Accounts Receivable Turnover |
0.48 | 1.15 | 1.45 | 0.84 | 0.66 | 1.05 | 1.18 | 2.03 | 2.16 | 1.25 |
Accounts Payable Turnover |
1.07 | 1.13 | 1.03 | 1.08 | 0.92 | 1.14 | 1.36 | 1.17 | 1.97 | 1.24 |
Inventory Turnover |
1.11 | 1.69 | 2.07 | 2.00 | 1.44 | 2.21 | 2.59 | 2.11 | 3.35 | 1.97 |
Average Days of Payables |
204.21 | 307.81 | 339.77 | 325.44 | 400.56 | 274.30 | 288.19 | 256.27 | 242.89 | 179.64 |
Days of Inventory on Hand |
318.91 | 220.06 | 211.09 | 125.49 | 274.98 | 161.91 | 132.54 | 153.25 | 127.82 | 126.54 |
Average Receivables |
2.36 | 1.52 | 1.33 | 2.34 | 3.92 | 4.55 | 4.38 | 3.46 | 3.25 | 3.92 |
Average Payables |
0.83 | 1.22 | 1.33 | 1.43 | 1.47 | 1.70 | 1.81 | 2.05 | 1.84 | 2.08 |
Average Inventory |
0.80 | 0.81 | 0.66 | 0.77 | 0.94 | 0.88 | 0.95 | 1.14 | 1.08 | 1.30 |
Average Assets |
28.21 | 22.40 | 26.34 | 31.55 | 34.05 | 28.12 | 19.59 | 12.56 | 6.54 | 5.86 |
Average Common Equity |
22.57 | 14.69 | 14.31 | 15.56 | 16.19 | 12.68 | 10.25 | 7.20 | 2.57 | 1.30 |
Columns are period end dates